

August 29, 2022

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

We would like to inform that, we had inadvertently missed attaching cash flow statement while uploading our financial results for the year ended June 30, 2022, approved by the Board at its meeting held today.

Request you to kindly note that, initial submission made with the exchange, was made within the prescribed timeline and this is only a revision to the same, due to an inadvertent error as described above.

We are hereby re-uploading a full set of results, for your perusal.

Kindly take the same on record.

Thanking you.

Yours faithfully,  
**For Procter & Gamble Health Limited**

**ZEAL JAYESH** Digitally signed by  
**SHAH** ZEAL JAYESH SHAH  
Date: 2022.08.29  
19:28:48 +05'30'

**Zeal Shah**  
**Company Secretary**

**PROCTER & GAMBLE HEALTH LIMITED**

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai - 400 079.  
CIN No. L99999MH1967PLC013726, email: Investorgrivance.in@pg.com

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR AND QUARTER ENDED 30 JUNE 2022**



(₹ in lakhs)

Sl. No.	Particulars	(1)	(2)	(3)	(4)	(5)
		Three months ended 30th June 2022	Preceding three months ended 31st March 2022	Corresponding Three months ended 30th June 2021	Year ended 30th June 2022	Year ended 30th June 2021
		Audited	Un-audited	Audited	Audited	Audited
1.	Revenue from Operations	29,589.0	26,782.0	28,540.0	111,441.0	100,873.0
2.	Other Income	310.0	235.0	242.0	1,319.0	1,810.0
3.	<b>Total income (1+2)</b>	<b>29,899.0</b>	<b>27,017.0</b>	<b>28,782.0</b>	<b>112,760.0</b>	<b>102,683.0</b>
4.	Expenses					
	a) Cost of materials consumed	7,247.0	7,476.0	7,340.0	32,372.0	28,923.0
	b) Purchases of stock-in-trade	499.0	409.0	814.0	2,081.0	2,116.0
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	1,114.0	191.0	437.0	(475.0)	173.0
	d) Employee benefits expense	4,213.0	4,500.0	4,659.0	16,756.0	15,366.0
	e) Depreciation and amortisation expense	747.0	612.0	716.0	2,708.0	3,004.0
	f) Impairment	73.0	-	-	73.0	-
	g) Finance Costs	2.0	14.0	18.0	42.0	80.0
	h) Other expenses	10,539.0	7,379.0	10,445.0	33,864.0	29,589.0
	<b>Total expenses (4)</b>	<b>24,434.0</b>	<b>20,531.0</b>	<b>24,429.0</b>	<b>87,423.0</b>	<b>79,355.0</b>
5.	<b>Profit before exceptional items and tax (3-4)</b>	<b>5,465.0</b>	<b>6,486.0</b>	<b>4,353.0</b>	<b>25,337.0</b>	<b>23,328.0</b>
6.	Less: Exceptional Items	-	-	-	-	-
7.	<b>Profit before tax (5-6)</b>	<b>5,465.0</b>	<b>6,486.0</b>	<b>4,353.0</b>	<b>25,337.0</b>	<b>23,328.0</b>
8.	Tax expenses					
	Current Tax	1,233.0	1,722.0	1,322.0	6,502.0	6,360.0
	Deferred Tax	113.0	(59.0)	(377.0)	4.0	(490.0)
	Tax for earlier years	-	(293.0)	19.0	(421.0)	(222.0)
9.	<b>Net Profit for the period/year (7-8)</b>	<b>4,119.0</b>	<b>5,116.0</b>	<b>3,389.0</b>	<b>19,252.0</b>	<b>17,680.0</b>
10.	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	I. Re-measurement gains/(losses) on defined benefit plans	324.0	128.0	551.0	94.0	56.0
	II. Income tax effect	(82.0)	(32.0)	(139.0)	(24.0)	(14.0)
	<b>Total Other Comprehensive Income, net of tax</b>	<b>242.0</b>	<b>96.0</b>	<b>412.0</b>	<b>70.0</b>	<b>42.0</b>
11.	<b>Total Comprehensive Income for the period/year (9+10)</b>	<b>4,361.0</b>	<b>5,212.0</b>	<b>3,801.0</b>	<b>19,322.0</b>	<b>17,722.0</b>
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	59,989.0	68,711.0
14.	Earnings per equity share (of Rs 10/- each) *(not annualised)					
	(a) Basic and Diluted (In Rs.)	* 24.8	* 30.8	* 20.4	* 116	* 106.5

**Notes:**

- The above audited financial results for the quarter and year ended June 30, 2022 have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on August 29, 2022.
- Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended.
- The figures of last quarter are the balancing figures between audited figures in respect of full year and published year to date figures upto the third quarter of financial year.
- The Board of Directors at its meeting held on August 29, 2022 has recommended for the current year final dividend of ₹ 11.5 per equity share (nominal value of ₹ 10 per equity share) amounting to ₹ 719.809 lakhs subject to approval of members at the ensuing Annual General Meeting of the Company.
- The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no segment information has been provided.
- Previous period figures have been regrouped/ reclassified wherever necessary.

For and on behalf of the Board of Directors of Procter & Gamble Health Limited

  
  
 Milind Thatte  
 Managing Director

Place : Mumbai  
Date : 29 August 2022  
Please visit us at our website [www.pghealthindia.com](http://www.pghealthindia.com)



**PROCTER & GAMBLE HEALTH LIMITED**

Notes:

**1. Statement of Assets and Liabilities**

(₹ in lakhs)

	As at June 30, 2022 [Audited]	As at June 30, 2021 [Audited]
<b>Non-current assets</b>		
(a) Property, plant and equipment	10,635	9,337
(b) Capital work-in-progress	4,060	3,915
(c) Investment property	260	295
(d) Right-of-use assets	267	747
(e) Intangible assets	4	12
(f) Financial assets		
(i) Loans	599	541
(ii) Other financial assets	876	818
(g) Deferred tax assets (Net)	1,965	1,991
(h) Other non-current assets	956	609
(i) Non-current tax assets (Net)	8,386	7,637
<b>Total non-current assets</b>	<b>28,008</b>	<b>25,902</b>
<b>Current assets</b>		
(a) Inventories	11,521	11,837
(b) Financial assets		
(i) Trade receivables	8,344	5,981
(ii) Cash and cash equivalents	31,940	46,405
(iii) Bank balances other than (ii) above	513	486
(iv) Loans	157	145
(v) Other financial assets	746	560
(c) Other current assets	8,143	7,300
<b>Total current assets</b>	<b>61,364</b>	<b>72,714</b>
<b>TOTAL ASSETS</b>	<b>89,372</b>	<b>98,616</b>
<b><u>EQUITY AND LIABILITIES</u></b>		
<b>Equity</b>		
(a) Equity share capital	1,660	1,660
(b) Other equity	59,989	68,711
<b>Total Equity</b>	<b>61,649</b>	<b>70,371</b>
<b>Non-Current Liabilities</b>		
(a) Financial liabilities		
(i) Lease liabilities	-	286
(c) Provisions	4,080	4,005
(b) Other non-current liabilities	60	57
<b>Total non-current liabilities</b>	<b>4,140</b>	<b>4,348</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Trade payables		
(i) total outstanding dues of micro enterprises and small enterprises	1,533	600
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises	16,068	17,291
(b) Lease Liabilities	283	475
(c) Other financial liabilities	3,025	2,367
(d) Provisions	1,026	1,917
(e) Current tax liabilities (net)	724	425
(f) Other current liabilities	924	822
<b>Total current liabilities</b>	<b>23,583</b>	<b>23,897</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>89,372</b>	<b>98,616</b>



*Mohan*

# Procter & Gamble Health Limited

## 2. Cash Flow Statement

	Year ended June 30, 2022 ₹ in lakhs	Year ended June 30, 2021 ₹ in lakhs
<b>A. Cash Flows from Operating Activities</b>		
Profit before tax	25 337	23 328
Adjustments for:		
Net unrealised foreign exchange loss	346	305
Allowance for doubtful receivables	159	108
Bad debts	7	48
Inventory written off	518	427
Provision/ write off of GST and other taxes	694	354
Depreciation of property, plant and equipment	2 708	3 004
Provision for Impairment	73	---
Income from letting of office premises	( 213)	( 209)
Provision for employee benefits	( 138)	537
Provision for sales return/ expiries	( 753)	706
Loss on sale of property, plant and equipment	54	42
Share-based payment to employees	341	193
Finance Cost	42	80
Interest income	( 1 107)	( 1 506)
<b>Operating profit before working capital changes</b>	<b>28 068</b>	<b>27 417</b>
Working capital adjustments:		
(Increase)/Decrease in inventories	( 202)	1 147
(Increase)/Decrease in trade receivables	( 2 515)	3 422
(Increase)/Decrease in financial and other Assets	( 2 201)	( 684)
(Decrease)/Increase in trade payables	( 650)	181
Increase in other liabilities and provisions	838	56
<b>Cash generated from operations</b>	<b>23 338</b>	<b>31 538</b>
Income taxes paid (net)	( 6 386)	( 6 812)
<b>Net cash generated from operating activities (A)</b>	<b>16 952</b>	<b>24 726</b>
<b>B. Cash Flows from Investing Activities</b>		
Purchase and construction of property, plant and equipment	( 3 792)	( 5 258)
Proceeds from sale of asset	37	121
Income from letting of office premises	213	209
Interest received	988	1 708
Security deposit placed against commitments	---	( 7)
<b>Net cash (used in)/ generated from investing activities (B)</b>	<b>( 2 554)</b>	<b>( 3 227)</b>
<b>C. Cash flow from financing activities</b>		
Dividend paid	( 28 385)	( 38 178)
Payment of lease liability	( 478)	( 485)
<b>Net cash flow used in financing activities (C)</b>	<b>( 28 863)</b>	<b>( 38 663)</b>
<b>Net (decrease)/ increase in cash and cash equivalents (A+B+C)</b>	<b>( 14 464)</b>	<b>( 17 164)</b>
Cash and cash equivalents at the beginning of the year	46 405	63 569
<b>Cash and cash equivalents at the end of the year</b>	<b>31 940</b>	<b>46 405</b>
<b>Components of Cash and Cash equivalents:</b>		
Cheque in hand	---	457
Balance with Banks		
In Current accounts	3 800	4 638
In Term deposits ( less than 3 months maturity)	28 140	41 310
	<b>31 940</b>	<b>46 405</b>

### Note:

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.



*[Handwritten signature]*